OncoMatch/Clinical Trials/NCT07342283
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Is NCT07342283 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Immunotherapy combined with chemotherapy for triple negative breast cancer (tnbc).
Treatment: Immunotherapy combined with chemotherapy — This is a single-center, single-arm, prospective study enrolling 30 patients with stage II-III triple-negative breast cancer. The neoadjuvant regimen consists of QL1706 combined with carboplatin plus albumin-bound paclitaxel (21-day cycles for 4 cycles) followed by QL1706 combined with doxorubicin/epirubicin plus cyclophosphamide (21-day cycles for 4 cycles). The treatment observation period is 1 year, and the primary endpoint is the pathological complete response rate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 negative (Allred score <3 or <1% positive) (Allred score <3 or <1% positively stained cells)
ER and PR with Allred score <3 or <1% positively stained cells in tumor infiltrating components
Required: PR (PGR) negative (Allred score <3 or <1% positive) (Allred score <3 or <1% positively stained cells)
ER and PR with Allred score <3 or <1% positively stained cells in tumor infiltrating components
Required: HER2 (ERBB2) negative (0 or 1+ by FISH or IHC per NCCN guidelines) (0 or 1+ by FISH or IHC)
HER2 negativity defined as 0 or 1+ by FISH or IHC staining per NCCN guidelines
Disease stage
Required: Stage II, III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Subjects who have received chemotherapy, immunotherapy, targeted therapy, or radiotherapy within the past 12 months
Cannot have received: immunotherapy
Subjects who have received chemotherapy, immunotherapy, targeted therapy, or radiotherapy within the past 12 months
Cannot have received: targeted therapy
Subjects who have received chemotherapy, immunotherapy, targeted therapy, or radiotherapy within the past 12 months
Cannot have received: radiation therapy
Subjects who have received chemotherapy, immunotherapy, targeted therapy, or radiotherapy within the past 12 months
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify